2 weeks Ago By Kim Min-jee
Celltrion has successfully extended the supply period for its breast and stomach cancer treatment, Herzuma (generic name: trastuzumab), in Brazil, the largest pharmaceutical market in Latin America. Celltrion has been rapidly enhancing its presence in the Latin American pharmaceutical market by achieving consecutive bidding successes. The company has extended supply contracts and secured new bids focused primarily on oncology drugs in key countries such as Brazil, Guatemala, and Costa Rica, establishing a stable revenue base and market dominance.
Brazil: Six Consecutive Years of Bidding Success with Herzuma Supply Until 2026 Celltrion successfully extended its supply contract for the breast and stomach cancer treatment Herzuma (generic name: trastuzumab) with the Brazilian government until March 2026. Brazil represents the largest pharmaceutical market in Latin America, and this bid is expected to account for approximately 97% of the total trastuzumab market, ensuring stable revenue for Herzuma in the future. Since 2020, Celltrion has maintained a record of five consecutive successful bids with the Brazilian government, further solidifying its brand credibility and market position.
Guatemala: Successful Bidding for Vegzelma Before Launch, Securing Market Lead In Guatemala, Celltrion achieved encouraging results by winning a bid from the central government's IGSS (Social Security Institute) for the metastatic colorectal and breast cancer treatment Vegzelma (generic name: bevacizumab). This will allow them to capture 95% of the market upon its official launch next month. Guatemala often continues supply contracts through extensions after bids expire, which increases the likelihood of long-term market dominance.
Currently, in Guatemala, Celltrion's hematologic cancer treatment Truxima holds the top prescription position with about 70% market share, and the addition of Vegzelma is expected to create synergies within their oncology portfolio. Costa Rica is also an important market for Celltrion. Here, Herzuma has a market share of nearly 95%, with additional supply secured until the first half of this year.
Supply through the social security office (CCSS) has been successful, and Celltrion has been winning bids annually since 2019 for both Herzuma and Truxima, reinforcing the company’s stronghold in the oncology sector. Combining Localization Strategy with Product Credibility to Accelerate Expansion of Future Products Celltrion's bidding success stems from its strategic approach, involving a detailed analysis of the characteristics and distribution structures of each country's pharmaceutical market. Building close networks with bidding agencies and local healthcare providers, alongside long-term product usage experiences, has significantly increased brand credibility.
Moving forward, Celltrion plans to sequentially launch follow-up products such as Remsima SC (the world’s first subcutaneous formulation of infliximab) and Yuflyma (generic name: adalimumab) to accelerate the expansion of its portfolio in the Latin American market. “The marketing capabilities and rich experiences of our local subsidiaries are creating synergies that drive our achievements," said Director Kang Kyung-doo, in charge of Celltrion’s Latin America division. "We will continuously strengthen our direct sales system to contribute to improving treatment accessibility and quality of life for patients in Latin America.
”.
